Fluorimetric Determination of Antiviral (COVID-19) Drug Favipiravir in Bulk and Pharmaceutical Dosage Forms
Abstract
Favipiravir is a synthetic prodrug, which was first discovered while assessing the antiviral activity of chemical agents active against the influenza virus in the chemical library of Toyoma chemicals. It works by inhibiting RNA dependant RNA polymerase (RdRP), an enzyme required for RNA viral replication inside human cells. A simple, rapid, and economic method was developed for the quantitative determination of Favipiravirusing spectrofluorometer. The Favipiravir standard drug solution and sample tablet solution was prepared using double distilled water as a diluent. The different concentrations ofpure drugin the range 2-10 μg/ml and one sample solution were measured for the intensity at 432nm in the spectrofluorometer. The calibration curve was plotted and the sample’s unknown concentration was calculated from the plot. The calibration curve was found to be linear with r2 value obtained as 0.99.There are various other methods available for the quantification of Favipiravir which include RP-HPLC, UV-spectroscopic methods, FTIR, LC-MS with different extraction methods spiked in human plasma but not by using spectrofluorometer. Favipiravir shows fluorescence when dissolved in appropriate solvent hencethis method was developed to quantify Favipiravir which is a simple and efficient method. This method developed is easy and can be used for routine quality control test for Favipiravir pharmaceutical formulations.
Keywords: Favipiravir, spectrofluorometer, Calibration curve.
Keywords:
Favipiravir, spectrofluorometer, Calibration curveDOI
https://doi.org/10.22270/jddt.v13i3.5770References
Furuta Y, Komeno T, et al., Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, P. Jpn. Acad. B-Phys. 2017; 93:449-463, https://doi.org/10.2183/pjab.93.027
Tanaka T, Kamiyama T, et al., T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: a beneficial feature of T-705 as an anti-influenza drug, Acta Virol. 2017; 61:48, https://doi.org/10.4149/av_2017_01_48
Bai C-Q, Mu J-S, et al., Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, Clin. Infect. Dis. 2014; 63(2016):1288-1294, https://doi.org/10.1093/cid/ciw571
Megahed SM, Habib AA, Hammad SF et al, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2021; 249. https://doi.org/10.1016/j.saa.2020.119241
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013 Nov; 100:446-454. https://doi.org/10.1016/j.antiviral.2013.09.015
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 50 -triphosphate towards influenza A virus polymerase. PloS One. 2013; 8:e68347. https://doi.org/10.1371/journal.pone.0068347
Megahed S, Habib A, Hammad S Kamal A, Experimental Design Approach for Development of Spectrofluorimetric Method for Determination of Favipiravir; a Potential Therapeutic Agent against COVID-19 Virus: Application to Spiked Human Plasma. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2020; 249:119241. https://doi.org/10.1016/j.saa.2020.119241
冯光玲丁文娟邓玉晓赵仁永龚艳艳段崇刚孙晋瑞, 2015, A kind of Favipiravir has the HPLC assay method of related substance, CN104914185B.
Taşkın D. Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation. Clinical and Experimental Health Sciences. 2022; 12(3):648-652. https://doi.org/10.33808/clinexphealthsci.992869
Hailat M, Al-Ani I, Hamad M, Zakareia Z, Abu Dayyih W. Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma. Molecules 2021; 26:3789. https://doi.org/10.3390/molecules26133789
Abdallah IA, Hammad SF, Bedair A, Elshafeey AH, Mansour FR. Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV. Bioanalysis. 2022; 14(4):205-216. Epub 2022 Jan 10. PMID: 35001648 https://doi.org/10.4155/bio-2021-0219
Onmaz DE, Abusoglu S, Onmaz M, Yerlikaya FH, Unlu A. Development and validation of a sensitive, fast and simple LC-MS/MS method for the quantitation of favipiravir in human serum. Journal of Chromatography B. 2021 Jun 30; 1176:122768. https://doi.org/10.1016/j.jchromb.2021.122768
RAGHAVENDRABABU PNN, PADMAVATHI Y, NEENA G, SUSHMA K, POOJITHA A. "NEW FTIR METHOD DEVELOPMENT AND VALIDATION FOR QUANTITATIVE ANALYSIS OF FAVIPIRAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORMS". International Journal of Current Pharmaceutical Research, 2022; 14(5):25-29, doi:10.22159/ijcpr.2022v14i5.2022.
https://doi.org/10.22159/ijcpr.2022v14i5.2022
Abdallah, I.A., El-Behairy, M.F., Ahmed, R.M. et al. The anti-COVID-19 drug Favipiravir: Degradation, Method development, Validation, NMR/LC-MS characterization, and In-vitro safety evaluation. Chem. Pap. 2022; 76:6415-6426. https://doi.org/10.1007/s11696-022-02327-5
Bulduk İ. Comparison of HPLC and UV Spectrophotometric Methods for Quantification of Favipiravir in Pharmaceutical Formulations. Iran J Pharm Res. 2021; 20(3):57-65. doi: 10.22037/ijpr.2020.114199.14725. PMID: 34903969; PMCID: PMC8653657.
El-Awady, M., Elmansi, H., Belal, F. et al. Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir. J Fluoresc 2022; 32:1941-1948. https://doi.org/10.1007/s10895-022-02998-z
Ramzy S, Abdelazim AH, Osman AOE, Hasan MA, Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Volume 2022; 281:121625, ISSN 1386-1425, https://doi.org/10.1016/j.saa.2022.121625
Published
Abstract Display: 476 
PDF Downloads: 581 PDF Downloads: 80 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.